Resilient prescribing is an approach to the use of psychotropics that considers the significance of the treatment beyond the direct effects of the medication. Within this strengths-based approach, those who are prescribed medications must retain a sense of self-efficacy, understand the importance of their own actions in their recovery, have reasonable expectations of what a medication can and cannot do, and avoid the adoption of a disempowering illness identity. These constitute the principles of resilient prescribing. In this manuscript, we explore these principles with consideration for how they may be applied in deployed settings where the ability of service members to recover from behavioral health concerns is mission critical. These principles offer a roadmap to prescribing that builds upon the service members' own strengths and has the potential to amplify the positive impacts of mental health treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/milmed/usad102 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The resilience of parents and carers who administer medicines to children at home: a qualitative systematic review protocol.
Syst Rev
January 2025
School of Healthcare, University of Leeds, Worsley Building, Leeds, LS2 9JT, UK.
Background: Parents and carers are increasingly expected to administer prescribed medicines to their children at home. However, parents and carers are not always able to administer medicines as directed by the prescriber and ultimately must rely on their own judgment to administer medicines safely. This process is often unseen but may contain important learning for professionals, academics, and wider society.
View Article and Find Full Text PDFThe impact of shelter-in-place during the COVID-19 pandemic on social support for mental health recovery: A prescribing-oriented qualitative study of patient perspectives.
PLoS One
January 2025
Kaiser Permanente San Jose Psychiatry, San Jose, California, United States of America.
The COVID-19 pandemic created unprecedented challenges for social connectivity and mental health, especially during mandated shelter-in-place periods. For patients engaged in mental health treatment, the social impact of their shelter-in-place experience remains an area of active investigation. This is particularly relevant in the context of social prescribing, a growing area of clinical intervention where healthcare providers actively refer patients to local social resources or activities to enhance mental health and wellbeing.
View Article and Find Full Text PDFWoody plant reinvasion shortens the lifespan of grassland restoration treatments.
J Environ Manage
January 2025
Department of Agronomy and Horticulture, University of Nebraska-Lincoln, Lincoln, NE, 68583, USA.
An important question in restoration ecology is whether restored ecological regimes are more vulnerable to transitions back to a degraded state. In woody-invaded grasslands, high-intensity fire can collapse woody plant communities and induce a shift back to a grass-dominated regime. Yet, legacies from woody-dominated regimes often persist and it remains unclear whether restored regimes are at heightened vulnerability to reinvasion.
View Article and Find Full Text PDFInterrogating green social prescribing in South Wales; A multi-stakeholder qualitative exploration.
PLoS One
January 2025
Swansea Community Farm, Swansea, Wales, United Kingdom.
Background: As an umbrella term, social prescribing offers varied routes into society which promise to support, enhance, and empower individual citizens to take control of their own health and wellbeing. Globally healthcare systems are struggling to cope with the increasing demands of an ageing population and the NHS (UK) is no exception. Social prescribing is heralded as a means to relieve the burden on primary care and provide support for the 20% of patients whose needs are non-medical.
View Article and Find Full Text PDFThe current state of mental health treatment for individuals diagnosed with major depressive disorder leaves billions of individuals with first-line therapies that are ineffective or burdened with undesirable side effects. One major obstacle is that distinct pathologies may currently be diagnosed as the same disease and prescribed the same treatments. The key to developing antidepressants with ubiquitous efficacy is to first identify a strategy to differentiate between heterogeneous conditions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!